Target intelligence / Profile preview

Splicing factor proline- and glutamine-rich (SFPQ)

Target
SFPQ
Molecular classification
RNA-binding protein, DNA-binding protein, Splicing factor, Transcriptional regulator, DBHS (Drosophila behavior human splicing) protein family
01

Overview

Splicing factor proline- and glutamine-rich (SFPQ) is a multifunctional nuclear RNA- and DNA-binding protein involved in alternative splicing, transcriptional regulation, RNA transport, DNA repair, and apoptosis. SFPQ is a member of the DBHS protein family and forms complexes with partners such as NONO/p54^nrb^ and PSPC1. It regulates vital cellular processes, including the control of pro- and antiapoptotic isoforms of caspases through modulation of alternative splicing factors (notably SRSF2). SFPQ is essential for cell viability; its upregulation is linked to platinum-chemoresistance in ovarian cancer and viral mRNA processing, and it interacts with several proteins including PTBP1 and NONO. Inhibition or knockdown of SFPQ leads to apoptosis and enhanced sensitivity to DNA-damaging agents.

Other names
PSFPTB-associated splicing factorhPOMp100PPP1R140100 kDa DNA-pairing proteinDNA-binding p52/p100 complexPolypyrimidine tract-binding protein-associated splicing factorprotein phosphatase 1 regulatory subunit 140POMP100epididymis secretory sperm binding proteinSFPQ/PSF
02

Mechanism of action

Drugs (cisplatin, carboplatin): induce DNA damage and apoptosis; SFPQ overexpression mediates resistance by promoting antiapoptotic transcripts via splicing regulation. Caspase inhibitors: block caspase activation downstream of SFPQ knockdown, rescuing cell viability.

03

Biological functions

Alternative RNA splicingTranscriptional activationTranscriptional repressionRNA transportRegulation of apoptosisDNA repair
04

Disease associations

Cancer (e.g., epithelial ovarian cancer, breast cancer chemoresistance)Neurodegenerative disease (research context)Viral infection (e.g., influenza virus mRNA processing)
05

Safety considerations

Overexpression in tumors is associated with chemoresistanceEssential for cell viability—systemic inhibition likely has off-target/cytotoxic effects
06

Interacting drugs

Cisplatin

2 more in the full profile.

07

Biomarkers

SFPQ expression levels (biomarker of platinum resistance in ovarian cancer)

Beyond the preview

Go deeper on Splicing factor proline- and glutamine-rich (SFPQ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Splicing factor proline- and glutamine-rich (SFPQ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call